Search - sphingotec.com

61. Proenkephalin (penKid®) included in the ADQI consensus statements publication as functional kidney biomarker for the management of AKI patients

SphingoTec GmbH (“SphingoTec”) announced today that the Acute Disease Quality Initiative (ADQI) recommends the use of novel biomarkers for AKI, including functional biomarkers as penKid®.

62. Uniklinik RWTH Aachen is the first hospital to implement SphingoTec's innovative biomarkers in clinical routine with the aim of making intensive care diagnostics more precise

The Uniklinik RWTH Aachen (“Uniklinik RWTH Aachen”) has successfully translated the collaboration for research and biomarker validation with SphingoTec GmbH (“SphingoTec”) into clinical routine.

63. SphingoTec, BHR Pharmaceuticals ink agreement for distribution of SphingoTec’s acute care portfolio in the UK and Ireland

BHR Pharmaceuticals Ltd (“BHR”) and SphingoTec GmbH (“SphingoTec”) today announced that they have signed a distribution agreement for the commercialization of SphingoTec’s portfolio of diagnostics…

64. SphingoTec’s kidney function biomarker penKid® accurately detects acute kidney injury in infants

Diagnostics company SphingoTec GmbH (“SphingoTec”) announced today the publication of first data, proving that its real-time kidney function biomarker penKid® is a reliable biomarker for the…

65. SphingoTec Issues Convertible Note Facility

Diagnostic company SphingoTec GmbH (SphingoTec) today announced that the Company has issued a non-brokered, unsecured convertible note facility amounting to EUR 5 million that was fully subscribed by…

66. SphingoTec to present at Solebury Trout's Summer Private Company Showcase

Diagnostics company SphingoTec GmbH (“SphingoTec”) today announced that Dr Andreas Bergman, CEO, and Ferdinand Von Humboldt, CFO, will be presenting a corporate overview at the Summer Private…

67. SphingoTec to present at LifeSci Partners' Summer Symposium

Diagnostics company SphingoTec GmbH (“SphingoTec”) today announced that Dr Andreas Bergman, CEO, and Ferdinand von Humboldt, CFO, will be presenting a corporate overview at the Private Healthcare…

68. SphingoTec launches point-of-care test for bio-ADM, a biomarker for life threatening endothelial dysfunction

Diagnostics company SphingoTec GmbH (“SphingoTec”) today announced the launch of its IB10 sphingotest® bio-ADM®, a CE-IVD-marked point-of-care test to quantitatively determine blood levels of…

69. Sphingotec’s critical care biomarkers early diagnose risk of loss of endothelial, kidney and heart function in severely ill COVID-19 patients

Diagnostics company SphingoTec GmbH (“sphingotec”) announced today the results of a working group meeting of clinical experts that discussed the utility of sphingotec’s diagnostic solutions for acute…

70. The cardiac depressant factor DPP3 is predicting organ failure in burn patients

Diagnostics company SphingoTec GmbH (“sphingotec”) and 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) announced today the publication of new data showing that high blood levels of Dipeptidyl Peptidase 3…